Alexis Rames
About
In The Last Decade
Alexis Rames
16 papers receiving 681 citations
Peers
Comparison fields: 5 of 97
- Physiology 401
- Pulmonary and Respiratory Medicine 259
- Immunology 118
- Immunology and Allergy 96
- Surgery 78
Countries citing papers authored by Alexis Rames
This map shows the geographic impact of Alexis Rames's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexis Rames with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexis Rames more than expected).
Fields of papers citing papers by Alexis Rames
This network shows the impact of papers produced by Alexis Rames. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexis Rames. The network helps show where Alexis Rames may publish in the future.
Co-authorship network of co-authors of Alexis Rames
This figure shows the co-authorship network connecting the top 25 collaborators of Alexis Rames. A scholar is included among the top collaborators of Alexis Rames based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexis Rames. Alexis Rames is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 63 | |
| 2 | 37 | |
| 3 | 11 | |
| 4 | 29 | |
| 5 | 26 | |
| 6 | 123 | |
| 7 | 32 | |
| 8 | 282 | |
| 9 | Long-term changes in the response of conductance and resistance coronary vessels to endothelium-dependent and independent vasodilators. A double-blind placebo-controlled study of the effect of a 6-month treatment with cilazapril. | 2 |
| 10 | Combining IIb/IIIa Inhibition and Heparin for Acute Coronary Syndromes: Evidence of a Gradient for Bleeding Hazard from the PARAGON Randomized Factorially Designed Trial | 2 |
| 11 | Delaying and Preventing Ischemic Events in Patients with Acute Coronary Syndromes Using the Platelet Glycoprotein IIb/IIIa Inhibitor Lamifiban | 8 |
| 12 | Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation in acute coronary syndromes | 4 |
| 13 | More Complete and Stable Reperfusion with Platelet IIb/IIIa Antagonism Plus Thrombolysis for AMI: The PARADIGM Trial | 16 |
| 14 | 29 | |
| 15 | 15 | |
| 16 | 35 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.